Skip to main content
Premium Trial:

Request an Annual Quote

At Lynx, Out With Russell, In With Corcoran -- and Money


Lynx Therapeutics has had its share of management topsy-turvy lately. After the company laid off 30 percent of its staff, longtime CEO Norrie Russell resigned and was replaced by vice president Kevin Corcoran, who has been at Lynx for seven years.

Craig Taylor, chairman of Lynx’s board, says the change in leadership came as a consequence of the company’s narrowed focus in the wake of its new $22.6 million financing round and layoffs. “With the force reduction, [there were] two things we put on hold for development: One was a program called Megatype and another was our genomic discovery group,” says Taylor. “Norrie had been head of discovery at Zeneca prior to their merger [with Astra], and he came to Lynx because he was pretty jazzed about the discovery capabilities of MPSS.”

At Lynx, Russell planned to “move up the value chain and become a drug company,” Taylor says. “We really decided to become a good old-fashioned information and tool company and not move up the value chain and become a drug company. We are really not doing what he wanted to do.”

Corcoran, on the other hand, “has been involved in the development of MPSS from day one,” Taylor says. As VP of operations, he worked to cement relationships with DuPont and Takara Bio. He also served on the development team for the company’s MPSS sequencing and gene expression technology and has spearheaded development of next-generation MPSS instruments. Corcoran came to Lynx from Applied Biosystems, where he held both technical and management positions.

Since the company’s new funding round, which closed in mid-April, Lynx has signed MPSS genotyping agreements with the National Cancer Institute, the Institute for Systems Biology, and Wilex, a cancer-focused biopharmaceutical company based in Munich.

The new wave of contracts, Taylor says, reflect the company’s desire to start making money and turn cash flow positive before the funding runs out. “That’s what the company is going to be about: Making money, not making discoveries,” he says.

— Marian Moser Jones

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.